+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Bladder Cancer: Dynamic Market Forecast to 2026

  • ID: 4530854
  • Report
  • March 2018
  • Region: Global
  • 54 pages
  • GlobalData


  • Abnoba
  • AstraZeneca
  • Clovis Oncology
  • Eli Lilly
  • Incyte
  • Merck KGaA
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Bladder Cancer: Dynamic Market Forecast to 2026


Bladder cancer is a rapidly evolving field in which new developments are constantly influencing the market landscape. The Dynamic Market Forecast is designed to help clients stay abreast of the latest news in the bladder cancer space, including regulatory, commercial, and clinical events as well as understand how all of these events will impact the projected market forecast.


The Dynamic Market Forecast consists of a slide deck detailing key market-impacting events that have occurred since the last publication of the Bladder Cancer report, which reflects the projected influence of these events on the future bladder cancer market.

The Key Events covered in this Bladder Cancer Dynamic Market Forecast include:
  • Developers Turn Focus to Combination Regimens
  • New Players Set to Shake Up NMIBC Space
Components of the slide deck include:
  • Timeline of market-impacting events
  • Key clinical trial landscape updates
  • Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective
  • Overview of updates to the forecast model based on anticipated future impact of events
  • Forward-looking events calendar listing expected key updates to the Bladder Cancer competitive space through December 2018
Other events included in the analysis include:
  • Regulatory filings
  • Approval decisions
  • Pricing changes
  • Patent litigation
  • Clinical trial data announcements
  • Clinical trial failures
  • Clinical trial timeline updates.
Reasons to buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global bladder cancer market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bladder cancer market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Note: Product cover images may vary from those shown


  • Abnoba
  • AstraZeneca
  • Clovis Oncology
  • Eli Lilly
  • Incyte
  • Merck KGaA
1. Dynamic Market Forecast Overview

2. Executive Summary
2.1 Key Updates To The Bladder Cancer Market Dynamic
2.2 Key Events Affecting The Bladder Cancer Competitive Landscape
2.3 Clinical Trial Landscape Updates
2.4 Competitive Landscape Changes
2.5 Market Insight On Key Events

3. Event 1: Developers Turn Focus To Combination Regimens
3.1 Key Updates To The Locally Advanced/Metastatic Setting
3.2 Roche, Tecentriq (atezolizumab)
3.3 Merck & Co., Keytruda (pembrolizumab)
3.4 AstraZeneca, Imfinzi (durvalumab) + tremelimumab
3.5 Pfizer and Merck KGaA , Bavencio (avelumab)
3.6 What Do Physicians Think?
3.7 Eli Lilly, Cyramza (ramucirumab)
3.8 Immunomedics, IMMU
3.9 Reimbursement In The UK Highlights Cost Effectiveness Concerns
3.10 Other Developments Of Interest
3.11 Summary/Trends
3.12 Sources

4. Event 2: New Players Set To Shake Up NMIBC Space
4.1 Key Updates To The NMIBC Space
4.2 Insight On Key Events
4.3 Summary/Trends
4.4 Sources

5. Events Calendar

6. Appendix
6.1 Methodology
6.2 Primary Research
Note: Product cover images may vary from those shown
  • Roche
  • Merck & Co.
  • AstraZeneca
  • Bristol-Myers Squibb (BMS)
  • Pfizer
  • Merck KGaA
  • Eli Lilly
  • Immunomedics
  • Incyte
  • Astellas
  • Bayer
  • Seattle Genetics
  • Tesaro
  • J&J
  • Altor Biosciences
  • Eleven Bio
  • FKD Therapies Oy
  • Clovis Oncology
  • Cold Genesys
  • Abnoba
  • Spectrum Pharmaceuticals
  • BioCanCell
Note: Product cover images may vary from those shown